PATIENT GUIDE. Highlights of Important Safety Information Warnings and Precautions. Your guide to treatment with Signifor LAR for acromegaly

Similar documents
TIPS FOR GETTING THE MOST OUT OF YOUR TREATMENT.

Managing Acromegaly: Review of Two Cases

Managing Acromegaly: Biochemical Control with SIGNIFOR LAR (pasireotide)

A medicine to block the amount of acid produced in the stomach (H2 blocker): about 10 hours before about 2 hours after

Getting started with PROMACTA (eltrombopag)

Open to the possibility of a multiple myeloma treatment that works in cells in your body at the DNA level

Treatment Journal. Therapy Tracker TREATMENT JOURNAL

THE REAL DEAL ABOUT GETTING STARTED

THE REAL DEAL ABOUT GETTING STARTED

Your guide to taking LENVIMA for hepatocellular carcinoma (HCC), a type of liver cancer

One daily pill can help prevent HIV. TRUVADA for PrEP, together with safer sex practices, can mean better protection.

Medication Tracker for ZYTIGA (abiraterone acetate)

READY. SET. DOPTELET. HELP GET READY FOR YOUR UPCOMING PROCEDURE

Discussing TECENTRIQ (atezolizumab) with your healthcare team Talking to Your Doctor

Tips to Help Treat Diarrhea, Nausea, and Vomiting Side Effects

Take CYCLOSET exactly as instructed by your health care provider, and be sure to read the Patient Information section of the package insert.

I. ALL CLAIMS: HEALTH CARE PROFESSIONALS

Starting KAZANO gave me MORE POWER than metformin alone, with 2 medicines in 1 tablet

PATIENT INFORMATION LEAFLET

MEDICATION GUIDE SUTENT

A GUIDE TO TREATMENT WHILE TAKING RYDAPT FOR ADVANCED SM

EMBRACING TODAY TOGETHER. A Guide For Caregivers

3 generations of ADPKD. 1 long-awaited treatment.

Patient s guide for switching to

PATIENT INFORMATION. CRESEMBA (Crē sem bah) (isavuconazonium sulfate) Capsules, for oral administration

Take on IPF progression with OFEV

Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension

AN ADVANCEMENT FOR POSTMENOPAUSAL WOMEN WITH ER+/HER2- METASTATIC BREAST CANCER.

What should I ask my treatment team?

YOUR CABOMETYX HANDBOOK

Rick N. EMPLICITI patient Ready to get started

KEEP LOVING. Because HIV doesn t change who you are.

ONE PILL, ONCE A DAY GET TO KNOW AUBAGIO. Ask your doctor if AUBAGIO may be right for you. Patient Portrayal

Could your uncontrollable movements be tardive dyskinesia (TD)? There s a treatment with INGREZZA.

TREATMENT PLAN WORKBOOK

PATIENT INFORMATION. Metformin Hydrochloride Extended-Release Tablets USP (met-for-min HYE-droe-KLOR-ide)

GLEEVEC PATIENT RESOURCES

MEDICATION GUIDE. Quetiapine (kwe-tye-a-peen) Tablets USP

Patient Information Losartan Potassium and Hydrochlorothiazide Tablets, USP 50 mg/12.5 mg, 100 mg/12.5 mg and 100 mg/25 mg Rx only

If you wake up to urinate 2 or more times a night, ask your doctor about NOCTIVA

Tuscarawas County Health Department. Vivitrol Treatment Consent

You are being asked to take octreotide as a treatment to manage the symptoms of your cancer.

Nivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions

MEDICATION GUIDE PegIntron (peg-in-tron) (Peginterferon alfa-2b) for injection, for subcutaneous use

Important Safety Information About TRUVADA to Reduce the Risk of Getting Human Immunodeficiency Virus 1 (HIV-1) Infection

FOR PATIENTS WITH SYMPTOMS OF SARCOIDOSIS. Treatment Journal. H.P. Acthar Gel is a prescription medication used to treat symptoms of sarcoidosis.

What are my treatment support resources?

Could your uncontrollable movements be tardive dyskinesia (TD)?

MEDICATION GUIDE XIGDUO XR (ZIG- DO- OH X- R) (dapagliflozin and metformin HCL extended-release) Tablets

MEDICATION GUIDE Mefloquine Hydrochloride Tablets, USP

Randy J. EMPLICITI patient Ready to get started

(sunitinib malate) for Kidney Cancer

YOUR GUIDE TO PATIENT SUPPORT SERVICES

Learning More Can Make a Difference

SAY HELLO TO CLEARER SKIN. SAY HELLO TO TREMFYA.

People who have received 1-3 prior treatments for their multiple myeloma may receive: Revlimid (lenalidomide)

Learn more about. about tikosyn (dofetilide)

DEDICATED SUPPORT TO HELP YOU GET STARTED AND STAY ON TRACK THROUGHOUT YOUR TREATMENT

PATIENT INFORMATION Metformin Hydrochloride Extended-Release Tablets (met-for-min HYE-droe-KLOR-ide) Rx only

Questions to ask your Doctor

GlaxoSmithKline Research Triangle Park, NC the ViiV Healthcare group of companies. All rights reserved. ZGN:XPI

ARIKAYCE IMPORTANT SAFETY INFORMATION

Discussion guide. Questions to bring to your next doctor s appointment. Notes

Have a healthy discussion. Use this guide to start a. conversation. with your. healthcare provider

How does my new treatment work?

For the Patient: USMAVNIV

Patient Information MICARDIS HCT (my-car-dis HCT) (telmisartan and hydrochlorothiazide) Tablets

Patient Information. Telmisartan and Hydrochlorothiazide (TEL-mi-SAR-tan and HYE-droe-KLOR-oh-THYE-a-zide) Tablets. Rx Only

severe diarrhea? Do you have ZINPLAVA is a medicine that helps reduce the risk that your C diff will come back.

WE RE IN A CONSTANT STRUGGLE. BUT WITH AFINITOR, WE VE FOUND ANOTHER OPTION.

For the Patient: ULUAVPMB

Medication Guide SEGLUROMET (seg-lur-oh-met) (ertugliflozin and metformin hydrochloride) tablets, for oral use

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

TAFINLAR + MEKINIST. for more moments FOR PATIENTS WITH A CERTAIN TYPE OF BRAF+ ADVANCED MELANOMA

Acthar TREATMENT JOURNAL

DISCOVER INVEGA TRINZA

A GUIDE TO STARTING TREATMENT

MEDICATION GUIDE. The risk of getting a serious skin rash is higher if you:

You matter and so does your health.


Getting started on MYALEPT (metreleptin) for injection

MEDICATION GUIDE. BENLYSTA (ben-list-ah) (belimumab) Injection for intravenous use

INVOKAMET (canagliflozin and metformin hydrochloride) tablets

Patient Information ALVESCO [ael- ves-koʊ] (ciclesonide) Inhalation Aerosol. Do not use your ALVESCO Inhalation Aerosol near heat or an open flame.

What You Need to Know About ARZERRA (ofatumumab)

What is the most important information I should know about carbamazepine tablets or chewable tablets?

Patient Information Entecavir Tablets (en-tek-ah-veer)

MEDICATION GUIDE. Peganone 250 mg Tablets (PEG-ah-noan) (ethotoin tablets, USP)

A GUIDE TO TALKING WITH YOUR DOCTOR ABOUT EPIDIOLEX

Patient Information IXEMPRA Kit (pronounced as ǐk-'sĕm-pră) (ixabepilone) What is the most important information I should know about IXEMPRA?

Discover CRYSVITA and Redefine XLH TREATMENT

Patient Information VIREAD (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets and oral powder

Capecitabine. Other Names: Xeloda. About This Drug. Possible Side Effects. Warnings and Precautions

ALECENSA (alectinib) Fact Sheet

LIVING PROOF. 23% Reduction in the risk of death compared with standardof-care. A guide to combination treatment with RYDAPT

A Guide for Patients and Caregivers

FDA APPROVED MEDICATION GUIDE

Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review

Transcription:

PATIENT GUIDE Your guide to treatment with Signifor LAR for acromegaly Signifor LAR is indicated for the treatment of patients with acromegaly for whom surgery has not worked well enough or who cannot have surgery. Treatment with Signifor LAR may cause high blood sugar levels (hyperglycemia) and diabetes. Your health care provider should check your blood sugar level before you start receiving Signifor LAR and while you receive it. Tell your health care provider if you have any of these symptoms: excessive thirst urinate more than usual increased appetite with weight loss tiredness If you get hyperglycemia, your health care provider may give you medicine to lower your blood sugar. Your health care provider may also change your dose of Signifor LAR or ask you to stop receiving it.

Table of contents Before starting treatment Before starting treatment 3 How was Signifor LAR (pasireotide) for injectable suspension studied? 4 How will I receive treatment? 6 Resources and support 7 Possible serious side effects: high blood sugar 8 Other possible serious side effects 9 My treatment plan 10 Indication and Important Safety Information 11 Important things to remember 12 Treatment with Signifor LAR may cause your heart to beat slower (bradycardia) or cause changes in the electrical system of your heart (QT interval prolongation). Your health care provider should check your heart s electrical system with an ECG test prior to starting Signifor LAR and after 3 weeks in patients who may be at risk for electrical system problems. Call your health care provider right away if you experience any signs and symptoms such as: weakness dizziness fainting Beginning treatment with Signifor LAR (pasireotide) for injectable suspension is one step in what can be a long journey with this condition. The information in this brochure is intended to help you become familiar with Signifor LAR and how it works. What is Signifor LAR? Signifor LAR is a prescription medicine used to treat adults with acromegaly for whom surgery has not worked well enough or who cannot have surgery. What does my doctor need to know? 1 It s important to tell your doctor about your medical history before starting treatment with Signifor LAR. Please tell your health care provider if you: have high blood sugar (hyperglycemia) have diabetes have or have had heart problems, including an abnormal heart rate or rhythm or problems with the electrical system of your heart (QT prolongation) have a low level of potassium or magnesium in your blood have liver problems have gallstones (cholelithiasis) have any other medical conditions are pregnant or planning to become pregnant. Signifor LAR may harm your unborn baby. are breastfeeding or planning to breastfeed. It is not known if Signifor LAR passes into your breast milk. You and your health care provider should decide if you will receive Signifor LAR or breastfeed. You should not do both. Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Signifor LAR for injectable suspension is a type of medication called a somatostatin analog. 1 Somatostatin analogs work by suppressing secretion of growth hormone (GH), which can lead to decreases in insulin-like growth factor 1 (IGF-1). 1 Signifor LAR and other medicines may affect each other, causing side effects. Signifor LAR may affect the way other medicines work, and other medicines may affect how Signifor LAR works. Your health care provider may need to change your dose of Signifor LAR. Especially tell your health care provider if you take: medicines to control your heart beat (anti-arrhythmics) medicines to control your blood pressure (such as beta-blockers or calcium channel blockers) medicines to control the potassium and magnesium (electrolytes) levels in your body medicines that may affect the way the electrical system of your heart works (QT prolongation) cyclosporine bromocriptine Ask your health care provider for a list of these medicines if you are not sure. Know the medicines you take. Keep a list of them to show to your health care provider and pharmacist when you get a new medicine. 2 3

How was Signifor LAR (pasireotide) for injectable suspension studied? Study 1: Results of a study of people who either had at least 1 pituitary surgery or did not have pituitary surgery and who had never taken medication for acromegaly 1 How was Signifor LAR (pasireotide) for injectable suspension studied? (cont d) Study 2: Results of a study of people with acromegaly whose acromegaly was not controlled on another somatostatin analog 1 The people in this study showed a history of not responding to treatment with their current somatostatin analog. 31.3% had GH <2.5 µg/l and normalized IGF-1 after 12 months on Signifor LAR 98% vs of people with acromegaly on Signifor LAR had either a reduction in the volume of their pituitary tumor or no change during the study The median change in tumor volume was a reduction of 39.8% The change in tumor volume for these people ranged from a reduction of 97.6% to an increase of 16.9% 19.2% on another somatostatin analog. (The people in this group did not take the maximum dose of the somatostatin analog during the study.) All people in the same study taking either Signifor LAR or another somatostatin analog had smaller ring sizes, and other symptoms such as headache, fatigue, and perspiration were reduced 15.4% who took 40 mg of Signifor LAR every 4 weeks experienced a reduction in both GH and IGF-1 after 6 months 20% who took 60 mg of Signifor LAR every 4 weeks experienced a reduction in both GH and IGF-1 after 6 months vs vs 0% 0% 81% 70% of people with acromegaly who took 40 mg of Signifor LAR every 4 weeks had either a reduction in the volume of their pituitary tumor or no change during the study The median change in tumor volume was a reduction of 10.4% The change in tumor volume for these people ranged from a reduction of 74.5% to an increase of 19.4% who continued taking another somatostatin analog they had taken for at least 6 months before starting the study. (Approximately 75% of the people in this group did not take the maximum dose of the somatostatin analog they took during the study.) who continued taking another somatostatin analog they had taken for at least 6 months before starting the study. (Approximately 75% of the people in this group did not take the maximum dose of the somatostatin analog they took during the study.) of people with acromegaly who took 60 mg of Signifor LAR every 4 weeks had either a reduction in the volume of their pituitary tumor or no change during the study The median change in tumor volume was a reduction of 6.3% The change in tumor volume for these people ranged from a reduction of 66.7% to an increase of 14.5% Treatment with Signifor LAR may cause elevations in liver function tests; therefore, your health care provider may do blood tests to monitor your liver. Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include: diarrhea, gallstones, high blood sugar, and diabetes mellitus. These are not all the possible side effects of Signifor LAR. Treatment with Signifor LAR may affect your gallbladder (gallstones, cholelithiasis). Tell your health care provider right away if you experience any of the following signs and symptoms: sudden pain in the upper right stomach area (abdomen) sudden pain in the right shoulder or between your shoulder blades yellowing of the skin and whites of your eyes fever and chills nausea 4 5

How will I receive treatment? Signifor LAR (pasireotide) for injectable suspension must be given by a trained health care provider as an injection into the muscle of your buttocks (intramuscularly). 1 Your health care provider will tell you how much Signifor LAR you will receive and when you will receive it. 1 Your health care provider may change your dose of Signifor LAR or the length of time between your injections. Your health care provider will tell you how long you need to receive Signifor LAR. 1 Before you receive Signifor LAR for the first time, your health care provider should do a blood test to check your fasting blood sugar level, electrolyte levels, and your liver function. 1 Before you receive Signifor LAR for the first time and during your treatment, your health care provider should do a test to check your heart (electrocardiogram). 1 How should I store Signifor LAR? 1 46 F 36 F Signifor LAR is administered once a month. Signifor LAR comes as an injection in 3 dosages (20 mg, 40 mg, and 60 mg), and can only be given to you by a trained health care provider. 1 Store Signifor LAR in the refrigerator between 36 F to 46 F (2 C to 8 C). Take Signifor LAR out of the refrigerator at least 30 minutes before you will receive it to allow it to come to room temperature. Do not use Signifor LAR if it has been out of the refrigerator and at room temperature for more than 24 hours. Your health care provider should give you Signifor LAR right away after it is mixed. Keep Signifor LAR and all medicines out of the reach of children. Treatment with Signifor LAR may affect your pituitary hormone levels (pituitary insufficiency). Signifor LAR may reduce the pituitary hormones in your body. Your health care provider should do a blood test to check your pituitary hormone levels before starting Signifor LAR and during treatment. Tell your health care provider if you experience any of these symptoms: nausea and vomiting tiredness dizziness diarrhea low blood glucose levels loss of appetite weight loss Resources and support A SHARED COMMITMENT TO ENHANCED PITUITARY CARE PEAK is an education and access program for patients with certain pituitary disorders. The PEAK program can help you: Access your medication Navigate the insurance process Connect with patient organizations and support groups PEAK aims to make it easier for you to find the support you need. TO LEARN MORE ABOUT PEAK The PEAK team can be reached Monday Friday (8 am 8 pm ET) to answer any questions or concerns you may have. How to contact PEAK: Online: www.peakhelp.com By phone: 1-877-503-3377 Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include: diarrhea, gallstones, high blood sugar, and diabetes mellitus. Tell your health care provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Signifor LAR. For more information and to get advice about side effects, ask your health care provider or pharmacist. 6 7

Possible serious side effects: high blood sugar 1 Other possible serious side effects 1 High blood sugar (or hyperglycemia) and diabetes are possible serious side effects of treatment with Signifor LAR (pasireotide) for injectable suspension. One important part of managing side effects is making sure your blood sugar levels are regularly checked. When should my doctor check my blood sugar levels? Before you start treatment with Signifor LAR»»»»»»»»»»While you re receiving treatment with Signifor LAR If I do get hyperglycemia, how might my doctor help? Signs and symptoms of high blood sugar Tell your health care provider if you are: feeling very thirsty urinating more than usual hungrier than usual, with weight loss more tired than usual If you get hyperglycemia while receiving Signifor LAR, your health care provider may give you another medicine to lower your blood sugar. Your health care provider may also change your dose of Signifor LAR or advise you to stop receiving it. When it comes to side effects, each person may have a different experience. In addition to hyperglycemia, Signifor LAR (pasireotide) for injectable suspension may cause serious side effects, such as: slow heart rate (bradycardia). Signifor LAR can cause your heart to beat slower. People who have, or have had heart problems, or take certain medicines used to treat slow heart rate or that may cause a slow heart rate, are at higher risk for bradycardia. Tell your health care provider if you get any of these symptoms: weakness fainting or near fainting spells changes in the electrical system of your heart (QT interval prolongation). Tell your health care provider if you get any of these symptoms: weakness fainting or near fainting spells higher than normal liver function tests. Your health care provider should do blood tests to check your liver while you receive Signifor LAR. gallstones (cholelithiasis). Tell your health care provider if you get any of these symptoms: sudden pain in your upper right stomach area (abdomen) sudden pain in your right shoulder or between your shoulder blades yellowing of your skin and whites of your eyes fever with chills nausea low levels of pituitary hormones (pituitary insufficiency). Signifor LAR may reduce the pituitary hormones in your body. Your health care provider should do a blood test to check your pituitary hormone levels before you start receiving Signifor LAR and while you receive it. Tell your health care provider if you get any of these symptoms: nausea and vomiting tiredness diarrhea low blood glucose levels loss of appetite weight loss 8 9

My treatment plan Your doctor may use a treatment plan to help you stay on track with your therapy. The example plan below is for you and your doctor to fill out together. Your doctor may change your plan. Please bring the plan when you visit your doctor. The plan will help you remember some of the important parts of your treatment. My treatment goals My target growth hormone (GH) level is My target insulin-like growth factor 1 (IGF-1) level is Before I start treatment with Signifor LAR (pasireotide) for injectable suspension On / / my current GH level is On / / my current IGF-1 level is While I have treatment with Signifor LAR (After 3 months) On / / my GH level is (After 3 months) On / / my IGF-1 level is (After months) On / / my GH level is (After months) On / / my IGF-1 level is Other important things to talk to my doctor about What dose of Signifor LAR am I currently on? When will my dosage be reviewed? Has there been any change in my condition? Are there any lifestyle changes I should make? Before taking Signifor LAR: Tell your health care provider about all the medicines you take including over-thecounter medicines, vitamins, and herbal supplements. Especially tell your health care provider if you take medicine to control your heart beat (anti-arrhythmics) to control your blood pressure (such as beta-blockers or calcium channel blockers) to control potassium and magnesium (electrolytes) levels in your body that affects the electrical system in your heart (QT prolongation) cyclosporine bromocriptine Indication and Important Safety Information Signifor LAR (pasireotide) for injectable suspension INDICATION Signifor LAR is indicated for the treatment of patients with acromegaly for whom surgery has not worked well enough or who cannot have surgery. IMPORTANT SAFETY INFORMATION This information does not take the place of talking to your health care provider about your medical condition or your treatment. Signifor LAR may cause serious side effects described below. : Treatment with Signifor LAR may cause high blood sugar levels (hyperglycemia) and diabetes. Your health care provider should check your blood sugar level before you start receiving Signifor LAR and while you receive it. Tell your health care provider if you have any of these symptoms: excessive thirst urinate more than usual increased appetite with weight loss tiredness If you get hyperglycemia, your health care provider may give you medicine to lower your blood sugar. Your health care provider may also change your dose of Signifor LAR or ask you to stop receiving it. Treatment with Signifor LAR may cause your heart to beat slower (bradycardia) or cause changes in the electrical system of your heart (QT interval prolongation). Your health care provider should check your heart s electrical system with an ECG test prior to starting Signifor LAR and after 3 weeks in patients who may be at risk for electrical system problems. Call your health care provider right away if you experience any signs and symptoms such as: weakness fainting Treatment with Signifor LAR may cause elevations in liver function tests; therefore, your health care provider may do blood tests to monitor your liver. Treatment with Signifor LAR may affect your gallbladder (gallstones, cholelithiasis). Tell your health care provider right away if you experience any of the following signs and symptoms: sudden pain in the upper right stomach area (abdomen) Please see full Prescribing Information enclosed in pocket in back cover. sudden pain in the right shoulder or between your shoulder blades yellowing of the skin and whites of your eyes fever and chills nausea Treatment with Signifor LAR may affect your pituitary hormone levels (pituitary insufficiency). Signifor LAR may reduce the pituitary hormones in your body. Your health care provider should do a blood test to check your pituitary hormone levels before starting Signifor LAR and during treatment. Tell your health care provider if you experience any of these symptoms: nausea and vomiting tiredness diarrhea low blood glucose levels loss of appetite weight loss Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include: diarrhea, gallstones, high blood sugar, and diabetes mellitus. Tell your health care provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Signifor LAR. For more information and to get advice about side effects, ask your health care provider or pharmacist. Before taking Signifor LAR: Tell your health care provider about all the medicines you take including over-the-counter medicines, vitamins, and herbal supplements. Especially tell your health care provider if you take medicine to control your heart beat (anti-arrhythmics) to control your blood pressure (such as betablockers or calcium channel blockers) to control potassium and magnesium (electrolytes) levels in your body that affects the electrical system in your heart (QT prolongation) cyclosporine bromocriptine You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. 10 11

Important things to remember 1 Keep Signifor LAR (pasireotide) for injectable suspension and all medicines out of the reach of children Store Signifor LAR in the refrigerator between 36 F to 46 F (2 C to 8 C) Signifor LAR can only be given to you by a trained health care professional Tell your doctor if you have any side effect that bothers you or that does not go away You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Reference: 1. Signifor LAR [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2014. Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080 2015 Novartis Printed in USA 6/15 SIA-1116010